Browse PRTN3

Summary
SymbolPRTN3
Nameproteinase 3
Aliases PR-3; ACPA; C-ANCA; AGP7; MBT; myeloblastin; serine proteinase, neutrophil; Wegener granulomatosis autoantig ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasmic granule Secreted Cell membrane Peripheral membrane protein Extracellular side Membrane raft Peripheral membrane protein Extracellular side Note=Localizes predominantly to azurophil granules (primary secretory granules) in neutrophils (PubMed:2033050, PubMed:3198760, PubMed:7897245, PubMed:18462208). Secreted upon neutrophil stimulation by TNF-alpha, lipopolysaccharide (LPS), fMLP and CXCL8/IL8 or during neutrophil transmigration (PubMed:22266279, PubMed:28240246). Following secretion tethered to the cell membrane by CD177 (PubMed:18462208, PubMed:22266279).
Domain PF00089 Trypsin
Function

Serine protease that degrades elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV (in vitro) (PubMed:3198760, PubMed:2033050, PubMed:28240246). By cleaving and activating receptor F2RL1/PAR-2, enhances endothelial cell barrier function and thus vascular integrity during neutrophil transendothelial migration (PubMed:23202369). May play a role in neutrophil transendothelial migration, probably when associated with CD177 (PubMed:22266279).

> Gene Ontology
 
Biological Process GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0006909 phagocytosis
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0030099 myeloid cell differentiation
GO:0030100 regulation of endocytosis
GO:0030574 collagen catabolic process
GO:0032963 collagen metabolic process
GO:0044236 multicellular organism metabolic process
GO:0044243 multicellular organism catabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0045806 negative regulation of endocytosis
GO:0050764 regulation of phagocytosis
GO:0050765 negative regulation of phagocytosis
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0051051 negative regulation of transport
GO:0060627 regulation of vesicle-mediated transport
GO:0097028 dendritic cell differentiation
GO:0097029 mature conventional dendritic cell differentiation
Molecular Function GO:0004175 endopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0008236 serine-type peptidase activity
GO:0017171 serine hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-6803157: Antimicrobial peptides
R-HSA-140875: Common Pathway of Fibrin Clot Formation
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-140877: Formation of Fibrin Clot (Clotting Cascade)
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
R-HSA-449147: Signaling by Interleukins
Summary
SymbolPRTN3
Nameproteinase 3
Aliases PR-3; ACPA; C-ANCA; AGP7; MBT; myeloblastin; serine proteinase, neutrophil; Wegener granulomatosis autoantig ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PRTN3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPRTN3
Nameproteinase 3
Aliases PR-3; ACPA; C-ANCA; AGP7; MBT; myeloblastin; serine proteinase, neutrophil; Wegener granulomatosis autoantig ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PRTN3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.5 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPRTN3
Nameproteinase 3
Aliases PR-3; ACPA; C-ANCA; AGP7; MBT; myeloblastin; serine proteinase, neutrophil; Wegener granulomatosis autoantig ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PRTN3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6320.519
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3340.836
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0120.581
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2280.613
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3060.0655
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PRTN3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPRTN3
Nameproteinase 3
Aliases PR-3; ACPA; C-ANCA; AGP7; MBT; myeloblastin; serine proteinase, neutrophil; Wegener granulomatosis autoantig ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRTN3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPRTN3
Nameproteinase 3
Aliases PR-3; ACPA; C-ANCA; AGP7; MBT; myeloblastin; serine proteinase, neutrophil; Wegener granulomatosis autoantig ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRTN3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRTN3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPRTN3
Nameproteinase 3
Aliases PR-3; ACPA; C-ANCA; AGP7; MBT; myeloblastin; serine proteinase, neutrophil; Wegener granulomatosis autoantig ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRTN3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPRTN3
Nameproteinase 3
Aliases PR-3; ACPA; C-ANCA; AGP7; MBT; myeloblastin; serine proteinase, neutrophil; Wegener granulomatosis autoantig ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PRTN3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPRTN3
Nameproteinase 3
Aliases PR-3; ACPA; C-ANCA; AGP7; MBT; myeloblastin; serine proteinase, neutrophil; Wegener granulomatosis autoantig ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PRTN3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPRTN3
Nameproteinase 3
Aliases PR-3; ACPA; C-ANCA; AGP7; MBT; myeloblastin; serine proteinase, neutrophil; Wegener granulomatosis autoantig ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PRTN3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PRTN3.
ID Name Drug Type Targets #Targets
DB05161ElafinSmall MoleculeELANE, PRTN32